Comprehensive assessment of the association between estrogen receptor of alpha polymorphisms and the risk of prostate cancer: evidence from a meta-analysis
Metrics: PDF 750 views | HTML 1001 views | ?
Guang Li1,*, Meng Yang2,*, Xian Li3 and Shixiong Deng1
1Laboratory of Forensic Medicine and Bioinformatics, Chongqing Medical University, Chongqing, China
2Research Department, Children Hospital of Chongqing Medical University, Chongqing, China
3Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing, China
*These authors contributed equally to this work
Xian Li, email: firstname.lastname@example.org
Shixiong Deng, email: email@example.com
Keywords: estrogen receptor of alpha, polymorphisms, prostate cancer, meta-analysis
Received: June 22, 2017 Accepted: August 27, 2017 Published: September 21, 2017
We performed a meta analysis to access the relationship of estrogen receptor of alpha (ESRα) polymorphisms with the risk of prostate cancer (PC). Twenty-four case-control studies (including 5477 cases and 10708 controls) were recruited for meta-analysis. The strongest association with the risk of PC was observed between ESRα rs9340799 and rs2234693 under the two genotypic models of allele and codominance in the overall population (p < 0.05). Under the subgroup analysis of ethnicity, we observed that ESRα rs9340799 was significantly associated with the susceptibility to PC in European population (AvsG, p = 0.000; AAvsGG, p = 0.002), while there was no difference in Asian (AvsG, p = 0.493; AAvsGG, p = 0.736) or African population (AvsG, p = 0.800; AAvsGG, p = 0.788). The results also showed that significant association between rs2234693 and the susceptibility to PC in European (CvsT, p = 0.004; CCvsTT, p = 0.001) and Asian population (CvsT, p = 0.004; CCvsTT, p = 0.003), but not in African population (CvsT, p = 0.636; CCvsTT, p = 0.669). The meta-analysis indicated that ESRα rs9340799 and rs2234693 might contribute to susceptibility and development of PC in European population.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.